Mineralocorticoid receptor function in major depression

被引:143
作者
Young, EA
Lopez, JF
Murphy-Weinberg, V
Watson, SJ
Akil, H
机构
[1] Univ Michigan, Mental Hlth Res Inst, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA
关键词
D O I
10.1001/archpsyc.60.1.24
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Negative feedback regulation of the hypothalamic-pituitary-adrenal axis occurs through a dual-receptor system of mineralocorticoid receptors (MR) and glucocorticoid receptors (GR). Their affinity for cortisol and their distribution in the brain differ. Studies using an MR antagonist have demonstrated that MR is active throughout the circadian rhythm. Because major depression is accompanied by increased glucocorticoid secretion and insensitivity to glucocorticoid feedback, and because glucocorticoids are capable of down-regulating MR and GR, we expected that major depression would be accompanied by decreased MR activity. Methods: To test this hypothesis, we administered spironolactone, an MR antagonist, to individuals with major depression and matched control subjects and assessed levels of corticotropin and cortisol secretion in response to this acute challenge. Studies were conducted in the morning, the time of peak activation of the hypothalamic-pituitary-adrenal axis. All patients were currently depressed and free of all medications. All controls were free of all psychiatric diagnoses and of all medications. Results: Spironolactone treatment resulted in a significant increase in cortisol secretion levels in both groups. Depressed patients demonstrated higher cortisol secretion levels than control subjects. in addition, depressed patients demonstrated a different pattern of increase in cortisol secretion levels after spironolactone administration. Furthermore, a significant effect of spironolactone treatment on corticotropin secretion levels can be observed in depressed patients, whereas controls show no such effect. Conclusions: Despite high baseline cortisol levels, patients with major depression show high functional activity of the MR system. Paired with the body of evidence regarding decreased sensitivity to GR agonists, these data suggest an imbalance in the MR/GR ratio. The balance of MR and GR is known to affect brain serotonin systems and may play an etiologic role in serotonin receptor changes observed in patients with major depression.
引用
收藏
页码:24 / 28
页数:5
相关论文
共 45 条
[31]  
PEROUTKA SJ, 1980, J PHARMACOL EXP THER, V215, P582
[32]  
PFOHL B, 1985, ARCH GEN PSYCHIAT, V42, P897
[33]   ON THE ROLE OF BRAIN MINERALOCORTICOID (TYPE-I) AND GLUCOCORTICOID (TYPE-II) RECEPTORS IN NEURO-ENDOCRINE REGULATION [J].
RATKA, A ;
SUTANTO, W ;
BLOEMERS, M ;
DEKLOET, ER .
NEUROENDOCRINOLOGY, 1989, 50 (02) :117-123
[34]   2 RECEPTOR SYSTEMS FOR CORTICOSTERONE IN RAT-BRAIN - MICRODISTRIBUTION AND DIFFERENTIAL OCCUPATION [J].
REUL, JMHM ;
DEKLOET, ER .
ENDOCRINOLOGY, 1985, 117 (06) :2505-2511
[35]  
RUBIN RT, 1987, ARCH GEN PSYCHIAT, V44, P328
[36]   GLUCOCORTICOID FEEDBACK INHIBITION OF ADRENOCORTICOTROPIC HORMONE SECRETAGOGUE RELEASE - RELATIONSHIP TO CORTICOSTEROID RECEPTOR OCCUPANCY IN VARIOUS LIMBIC SITES [J].
SAPOLSKY, RM ;
ARMANINI, MP ;
PACKAN, DR ;
SUTTON, SW ;
PLOTSKY, PM .
NEUROENDOCRINOLOGY, 1990, 51 (03) :328-336
[37]   NEURONAL CIRCUITS INVOLVED IN THE ANXIOLYTIC EFFECTS OF THE 5-HT1A RECEPTOR AGONISTS 8-OH-DPAT, IPSAPIRONE AND BUSPIRONE IN THE RAT [J].
SCHREIBER, R ;
DEVRY, J .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 249 (03) :341-351
[38]   ADRENAL-STEROID TYPE-I AND TYPE-II RECEPTOR-BINDING - ESTIMATES OF INVIVO RECEPTOR NUMBER, OCCUPANCY, AND ACTIVATION WITH VARYING LEVEL OF STEROID [J].
SPENCER, RL ;
YOUNG, EA ;
CHOO, PH ;
MCEWEN, BS .
BRAIN RESEARCH, 1990, 514 (01) :37-48
[39]   Heterodimerization between mineralocorticoid and glucocorticoid receptors increases the functional diversity of corticosteroid action [J].
Trapp, T ;
Holsboer, F .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1996, 17 (04) :145-149
[40]   AUTORADIOGRAPHIC QUANTIFICATION OF SEROTONIN1A RECEPTORS IN RAT-BRAIN FOLLOWING ANTIDEPRESSANT DRUG-TREATMENT [J].
WELNER, SA ;
DEMONTIGNY, C ;
DESROCHES, J ;
DESJARDINS, P ;
SURANYICADOTTE, BE .
SYNAPSE, 1989, 4 (04) :347-352